Gene network disruptions and neurogenesis defects in the adult Ts1Cje mouse model of Down syndrome.

<h4>Background</h4>Down syndrome (DS) individuals suffer mental retardation with further cognitive decline and early onset Alzheimer's disease.<h4>Methodology/principal findings</h4>To understand how trisomy 21 causes these neurological abnormalities we investigated chan...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chelsee A Hewitt, King-Hwa Ling, Tobias D Merson, Ken M Simpson, Matthew E Ritchie, Sarah L King, Melanie A Pritchard, Gordon K Smyth, Tim Thomas, Hamish S Scott, Anne K Voss
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2010
Materias:
R
Q
Acceso en línea:https://doaj.org/article/9f51062a00a048609ce9234d5876a4cf
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:<h4>Background</h4>Down syndrome (DS) individuals suffer mental retardation with further cognitive decline and early onset Alzheimer's disease.<h4>Methodology/principal findings</h4>To understand how trisomy 21 causes these neurological abnormalities we investigated changes in gene expression networks combined with a systematic cell lineage analysis of adult neurogenesis using the Ts1Cje mouse model of DS. We demonstrated down regulation of a number of key genes involved in proliferation and cell cycle progression including Mcm7, Brca2, Prim1, Cenpo and Aurka in trisomic neurospheres. We found that trisomy did not affect the number of adult neural stem cells but resulted in reduced numbers of neural progenitors and neuroblasts. Analysis of differentiating adult Ts1Cje neural progenitors showed a severe reduction in numbers of neurons produced with a tendency for less elaborate neurites, whilst the numbers of astrocytes was increased.<h4>Conclusions/significance</h4>We have shown that trisomy affects a number of elements of adult neurogenesis likely to result in a progressive pathogenesis and consequently providing the potential for the development of therapies to slow progression of, or even ameliorate the neuronal deficits suffered by DS individuals.